AKT1 and fibrosis: In conclusion, our findings support the extension of the targeting of the FAK/PI3K/AKT and TGF-β signaling pathways as an anti-fibrotic strategy in fibrosis skin, and Zyxin appears to be a potent therapeutic target against skin fibrosis.